Uncovering a novel pathway for p16 silencing: Therapeutic implications for lung cancer

C. Gamell; T. Gulati; B. Solomon; S. Haupt; Y. Haupt

doi:10.1080/23723556.2017.1299273

Uncovering a novel pathway for p16 silencing: Therapeutic implications for lung cancer

C. Gamell, T. Gulati, B. Solomon, S. Haupt, Y. Haupt

Biochemistry & Molecular Biology

Research output: Contribution to journal › Article › Research › peer-review

5 Citations (Scopus)

Abstract

A key step during onset of most cases of non-small cell lung cancer (NSCLC) is the loss of the tumor suppressor p16^INK4a (best known as p16), commonly due to promoter hypermethylation. We recently reported a novel regulatory pathway involving E6-associated protein and cell division control protein 6, which provides a methylation-independent mechanism for p16 silencing in patients with a particularly aggressive form of NSCLC.

Original language	English
Article number	e1299273
Number of pages	3
Journal	Molecular and Cellular Oncology
Volume	4
Issue number	5
DOIs	https://doi.org/10.1080/23723556.2017.1299273
Publication status	Published - 3 Sep 2017

Keywords

CDC6
E6AP
INK4/ARF
NSCLC
p16
tumor suppression

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/23723556.2017.1299273

248484531-oaFinal published version, 170 KB

Cite this

@article{f336aa4b497f4901a20c28f081a9cdca,

title = "Uncovering a novel pathway for p16 silencing: Therapeutic implications for lung cancer",

abstract = "A key step during onset of most cases of non-small cell lung cancer (NSCLC) is the loss of the tumor suppressor p16INK4a (best known as p16), commonly due to promoter hypermethylation. We recently reported a novel regulatory pathway involving E6-associated protein and cell division control protein 6, which provides a methylation-independent mechanism for p16 silencing in patients with a particularly aggressive form of NSCLC.",

keywords = "CDC6, E6AP, INK4/ARF, NSCLC, p16, tumor suppression",

author = "C. Gamell and T. Gulati and B. Solomon and S. Haupt and Y. Haupt",

year = "2017",

month = sep,

day = "3",

doi = "10.1080/23723556.2017.1299273",

language = "English",

volume = "4",

journal = "Molecular and Cellular Oncology",

issn = "2372-3556",

publisher = "Taylor & Francis",

number = "5",

}

TY - JOUR

T1 - Uncovering a novel pathway for p16 silencing

T2 - Therapeutic implications for lung cancer

AU - Gamell, C.

AU - Gulati, T.

AU - Solomon, B.

AU - Haupt, S.

AU - Haupt, Y.

PY - 2017/9/3

Y1 - 2017/9/3

N2 - A key step during onset of most cases of non-small cell lung cancer (NSCLC) is the loss of the tumor suppressor p16INK4a (best known as p16), commonly due to promoter hypermethylation. We recently reported a novel regulatory pathway involving E6-associated protein and cell division control protein 6, which provides a methylation-independent mechanism for p16 silencing in patients with a particularly aggressive form of NSCLC.

AB - A key step during onset of most cases of non-small cell lung cancer (NSCLC) is the loss of the tumor suppressor p16INK4a (best known as p16), commonly due to promoter hypermethylation. We recently reported a novel regulatory pathway involving E6-associated protein and cell division control protein 6, which provides a methylation-independent mechanism for p16 silencing in patients with a particularly aggressive form of NSCLC.

KW - CDC6

KW - E6AP

KW - INK4/ARF

KW - NSCLC

KW - p16

KW - tumor suppression

UR - http://www.scopus.com/inward/record.url?scp=85050752136&partnerID=8YFLogxK

U2 - 10.1080/23723556.2017.1299273

DO - 10.1080/23723556.2017.1299273

M3 - Article

AN - SCOPUS:85050752136

VL - 4

JO - Molecular and Cellular Oncology

JF - Molecular and Cellular Oncology

SN - 2372-3556

IS - 5

M1 - e1299273

ER -

Uncovering a novel pathway for p16 silencing: Therapeutic implications for lung cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Cite this